Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 75/100

Failure Rate

25.0%

1 terminated/withdrawn out of 4 trials

Success Rate

50.0%

-36.5% vs industry average

Late-Stage Pipeline

25%

1 trials in Phase 3/4

Results Transparency

0%

0 of 1 completed trials have results

Key Signals

2 recruiting

Enrollment Performance

Analytics

Phase 1
2(50.0%)
Phase 3
1(25.0%)
Phase 2
1(25.0%)
4Total
Phase 1(2)
Phase 3(1)
Phase 2(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (4)

Showing 4 of 4 trials
NCT05859464Phase 1Terminated

A Phase 1 Study of ZL-1218 in Subjects With Advanced Solid Tumors

Role: lead

NCT06380907Phase 2Recruiting

A Phase 2 Study of ZL-1102 in Patients With Chronic Plaque Psoriasis

Role: lead

NCT06462326Phase 1Completed

A Study to Compare the Effect of Omadacycline Versus Moxifloxacin in Healthy Adult Volunteers

Role: lead

NCT06162286Phase 3Recruiting

A Phase 3b Randomized, Double-blind, Multi-center Study to Compare the Safety and Efficacy of Omadacycline to Moxifloxacin for Treating Adult Subjects With CABP

Role: lead

All 4 trials loaded